# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Cavernous angioma

Cavernous hemangiomaCerebral cavernous malformation (CCM)Cavernoma
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-7 of 7 results.
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Status: Recruiting
Last Changed: Aug 29, 2018
First Received: Aug 29, 2018
Disease(s): CCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1, Cerebral Cavernous Malformations 2, Cerebral Cavernous Malformations 3, Cavernous Angioma
Locations: The University of Chicago Medical Center, Chicago, Illinois, United States
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Status: Recruiting
Last Changed: Oct 04, 2018
First Received: Nov 11, 2015
Disease(s): Cerebral Cavernous Malformation
Intervention(s): Atorvastatin, Placebo
Locations: University of Chicago, Chicago, Illinois, United States
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Status: Recruiting
Last Changed: Aug 08, 2019
First Received: Jan 09, 2013
Disease(s): Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
Locations: Barrow Neurological Institute, Phoenix, Arizona, United States
University of California, San Francisco, San Francisco, California, United States
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Angioma Alliance, Durham, North Carolina, United States
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Status: Recruiting
Last Changed: Sep 04, 2019
First Received: Sep 02, 2019
Disease(s): Cavernous Malformation, Cerebral, Cavernous Angioma, Cavernous Hemangioma, Cavernous Hemangioma of Brain, Seizures, Seizures, Epileptic, Epilepsy
Locations: Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
Peking University International Hospital, Beijing, Beijing, China
Treat_CCM: Propranolol in Cerebral Cavernous Malformation
Status: Recruiting
Last Changed: May 02, 2019
First Received: Jul 17, 2018
Disease(s): Cerebral Cavernous Malformation
Intervention(s): Propranolol
Locations: IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy
IRCCS Centro Neurolesi "Bonino Pulejo", Messina, ME, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Mi, Italy
Fond. IRCCS Ist. Naz. Neurologico Carlo Besta, Milano, MI, Italy
ASST Grande Ospedale Metropolitano Niguarda, Milano, MI, Italy
... and 2 other locations.
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
Status: Recruiting
Last Changed: Mar 19, 2018
First Received: Mar 16, 2018
Disease(s): Cerebral Cavernous Malformations
Intervention(s): Surgery, Observation
Locations: The first affiliated hospital of fujian medical university, Fuzhou, Fujian, China
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
Status: Recruiting
Last Changed: Mar 22, 2018
First Received: Mar 22, 2018
Disease(s): Cerebral Cavernous Malformations
Intervention(s): Propranolol, DNA and RNA Analysis
Locations: Barrow Neurological Institute, Phoenix, Arizona, United States